[go: up one dir, main page]

WO2006030306A3 - Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder - Google Patents

Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder Download PDF

Info

Publication number
WO2006030306A3
WO2006030306A3 PCT/IB2005/002769 IB2005002769W WO2006030306A3 WO 2006030306 A3 WO2006030306 A3 WO 2006030306A3 IB 2005002769 W IB2005002769 W IB 2005002769W WO 2006030306 A3 WO2006030306 A3 WO 2006030306A3
Authority
WO
WIPO (PCT)
Prior art keywords
premenstrual
pindolol
treating
dysphoric disorder
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002769
Other languages
French (fr)
Other versions
WO2006030306A2 (en
WO2006030306A8 (en
Inventor
Timothy Dinan
Peter Daly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroCure Ltd
Original Assignee
NeuroCure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroCure Ltd filed Critical NeuroCure Ltd
Priority to EP05779646A priority Critical patent/EP1793818A2/en
Priority to AU2005283829A priority patent/AU2005283829A1/en
Priority to US11/663,075 priority patent/US20080262071A1/en
Priority to JP2007531860A priority patent/JP2008513430A/en
Publication of WO2006030306A2 publication Critical patent/WO2006030306A2/en
Publication of WO2006030306A3 publication Critical patent/WO2006030306A3/en
Anticipated expiration legal-status Critical
Publication of WO2006030306A8 publication Critical patent/WO2006030306A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

In accordance with the present invention, it has been discovered that pindolol provides a highly effective treatment for PMS and/or PMDD. As such, the present invention generally relates to methods and compositions for treating and/or preventing PMS, or symptoms associated therewith including premenstrual tension or premenstrual dysphoria. The methods and compositions of the invention also involves the use of pindolol, a known beta adrenergic blocker, in combination with known contraceptives.
PCT/IB2005/002769 2004-09-17 2005-09-19 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder Ceased WO2006030306A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05779646A EP1793818A2 (en) 2004-09-17 2005-09-19 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
AU2005283829A AU2005283829A1 (en) 2004-09-17 2005-09-19 Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
US11/663,075 US20080262071A1 (en) 2004-09-17 2005-09-19 Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
JP2007531860A JP2008513430A (en) 2004-09-17 2005-09-19 Pindolol for the treatment of premenstrual syndrome and premenstrual dysphoric disorder

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61061004P 2004-09-17 2004-09-17
US60/610,610 2004-09-17
US65494305P 2005-02-23 2005-02-23
US60/654,943 2005-02-23
US68671805P 2005-06-01 2005-06-01
US60/686,718 2005-06-01

Publications (3)

Publication Number Publication Date
WO2006030306A2 WO2006030306A2 (en) 2006-03-23
WO2006030306A3 true WO2006030306A3 (en) 2006-09-08
WO2006030306A8 WO2006030306A8 (en) 2007-10-04

Family

ID=35457136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002769 Ceased WO2006030306A2 (en) 2004-09-17 2005-09-19 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder

Country Status (4)

Country Link
EP (1) EP1793818A2 (en)
JP (1) JP2008513430A (en)
AU (1) AU2005283829A1 (en)
WO (1) WO2006030306A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527378A (en) 1998-10-15 2002-08-27 インペリアル・カレッジ・イノベイションズ・リミテッド Method of treatment
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A2 (en) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1999002142A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham P.L.C. Novel composition comprising an ssri and a beta-blocker
US20020165263A1 (en) * 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A2 (en) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1999002142A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham P.L.C. Novel composition comprising an ssri and a beta-blocker
US20020165263A1 (en) * 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARKER P D: "Premenstrual syndrome.", AMERICAN FAMILY PHYSICIAN. 1 NOV 1994, vol. 50, no. 6, 1 November 1994 (1994-11-01), pages 1309 - 1317 , 13, XP008062633, ISSN: 0002-838X *
RAUSCH J L ET AL: "ATENOLOL TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER", JOURNAL OF AFFECTIVE DISORDERS, vol. 15, no. 2, 1988, pages 141 - 147, XP002375780, ISSN: 0165-0327 *

Also Published As

Publication number Publication date
JP2008513430A (en) 2008-05-01
AU2005283829A1 (en) 2006-03-23
WO2006030306A2 (en) 2006-03-23
EP1793818A2 (en) 2007-06-13
WO2006030306A8 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
PH12013500355A1 (en) Engineered anti-tslp antibody
WO2008097640A8 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2007139967A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139955A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139968A3 (en) Triazole compounds that modulate hsp90 activity
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
TW200732296A (en) Novel compounds
MX2009008135A (en) Use of chromium histidinate for treatment of cardiometabolic disorders.
TW200640454A (en) Method for treating obesity
WO2004112786A3 (en) Gaboxadol for treating depression and other affective disorders
WO2010106542A3 (en) USE OF NKp46 FOR PREVENTING DIABETES
WO2008121386A3 (en) Calcimimetic compounds for use in the treatment of bowel disorders
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2006102061A3 (en) Methods of decreasing calcification
WO2006122123A3 (en) Methods of alleviating disorders and their associated pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005779646

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007531860

Country of ref document: JP

Ref document number: 2005283829

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005283829

Country of ref document: AU

Date of ref document: 20050919

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005283829

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005779646

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11663075

Country of ref document: US